Sign in
LGVN Stock Price, Chart, Stats & News
Longeveron Inc.
Save
14.13M
Market cap
–
Current P/E
–
Forward P/E
LGVN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 43.70% |
Operating margin | -1942.20% |
Pretax margin | -1893.58% |
Net margin | -1893.58% |
Effective tax rate | – |
ROA | -221.26% |
ROE | -199.79% |
D/E | 0.15x |
Interest coverage ratio | – |
LGVN valuation
P/E | – |
P/S | 17.88x |
P/B | 3.72x |
P/CF | -1.13x |
P/FCF | -1.12x |
P/OCF | -1.13x |
PEG | -0.41x |
EV multiple | -1.17x |
About
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy.
Similar securities
Based on sector and market capitalization
Report issue